Antibiotic-non-antibiotic combinations for combating extremely drug-resistant Gram-negative 'superbugs'
- PMID: 28258235
- DOI: 10.1042/EBC20160058
Antibiotic-non-antibiotic combinations for combating extremely drug-resistant Gram-negative 'superbugs'
Abstract
The emergence of antimicrobial resistance of Gram-negative pathogens has become a worldwide crisis. The status quo for combating resistance is to employ synergistic combinations of antibiotics. Faced with this fast-approaching post-antibiotic era, it is critical that we devise strategies to prolong and maximize the clinical efficacy of existing antibiotics. Unfortunately, reports of extremely drug-resistant (XDR) Gram-negative pathogens have become more common. Combining antibiotics such as polymyxin B or the broad-spectrum tetracycline and minocycline with various FDA-approved non-antibiotic drugs have emerged as a novel combination strategy against otherwise untreatable XDR pathogens. This review surveys the available literature on the potential benefits of employing antibiotic-non-antibiotic drug combination therapy. The apex of this review highlights the clinical utility of this novel therapeutic strategy for combating infections caused by 'superbugs'.
Keywords: antibiotic-nonantibiotic combinations; antimicrobials; combination therapy; minocycline; polymyxin.
© 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.
Similar articles
-
Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.Comput Struct Biotechnol J. 2020 Aug 21;18:2247-2258. doi: 10.1016/j.csbj.2020.08.008. eCollection 2020. Comput Struct Biotechnol J. 2020. PMID: 32952938 Free PMC article.
-
Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria.Crit Rev Microbiol. 2019 May;45(3):301-314. doi: 10.1080/1040841X.2019.1599813. Epub 2019 Apr 15. Crit Rev Microbiol. 2019. PMID: 30985240 Review.
-
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Int J Antimicrob Agents. 2016 Dec;48(6):592-597. doi: 10.1016/j.ijantimicag.2016.09.010. Epub 2016 Oct 18. Int J Antimicrob Agents. 2016. PMID: 27793510 Free PMC article. Review.
-
Antimicrobial Peptide Novicidin Synergizes with Rifampin, Ceftriaxone, and Ceftazidime against Antibiotic-Resistant Enterobacteriaceae In Vitro.Antimicrob Agents Chemother. 2015 Oct;59(10):6233-40. doi: 10.1128/AAC.01245-15. Epub 2015 Jul 27. Antimicrob Agents Chemother. 2015. PMID: 26248380 Free PMC article.
-
Management of antibiotic resistance in the intensive care unit setting.Expert Rev Anti Infect Ther. 2010 Mar;8(3):289-302. doi: 10.1586/eri.10.7. Expert Rev Anti Infect Ther. 2010. PMID: 20192683 Review.
Cited by
-
Improving therapy of severe infections through drug repurposing of synergistic combinations.Curr Opin Pharmacol. 2019 Oct;48:92-98. doi: 10.1016/j.coph.2019.07.006. Epub 2019 Aug 24. Curr Opin Pharmacol. 2019. PMID: 31454708 Free PMC article. Review.
-
Synergism of fused bicyclic 2-aminothiazolyl compounds with polymyxin B against Klebsiella pneumoniae.Medchemcomm. 2017 Sep 14;8(11):2060-2066. doi: 10.1039/c7md00354d. eCollection 2017 Nov 1. Medchemcomm. 2017. PMID: 30108723 Free PMC article.
-
Non-antibiotic pharmaceuticals are toxic against Escherichia coli with no evolution of cross-resistance to antibiotics.NPJ Antimicrob Resist. 2024 Apr 15;2(1):11. doi: 10.1038/s44259-024-00028-5. NPJ Antimicrob Resist. 2024. PMID: 39843932 Free PMC article.
-
Zidovudine in synergistic combination with nitrofurantoin or omadacycline: in vitro and in murine urinary tract or lung infection evaluation against multidrug-resistant Klebsiella pneumoniae.Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0034424. doi: 10.1128/aac.00344-24. Epub 2024 Aug 28. Antimicrob Agents Chemother. 2024. PMID: 39194261 Free PMC article.
-
Rare occurrence of polymyxin B-induced hyperpigmentation in a child with ventriculitis.BMJ Case Rep. 2023 Apr 11;16(4):e253959. doi: 10.1136/bcr-2022-253959. BMJ Case Rep. 2023. PMID: 37041040 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous